Evidence map›Paper›PMID 40324778›Full record

ReviewHuman reproduction update2025

Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve.

Joshua Johnson, John W Emerson, Annika Smith, Kayla Medina, Evelyn E Telfer, Richard A Anderson, Sean D Lawley

Abstract readReview
In one paragraph

Review in Human reproduction update, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joshua JohnsonDivision of Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Colorado Denver (AMC), Aurora, CO, USA.ORCID 0000-0002-6016-8089
John W EmersonDepartment of Statistics and Data Science, Yale University, New Haven, CT, USA.
Annika SmithDivision of Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Colorado Denver (AMC), Aurora, CO, USA.
Kayla MedinaDivision of Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Colorado Denver (AMC), Aurora, CO, USA.
Evelyn E TelferInstitute of Cell Biology, Hugh Robson Building, University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-1468-4610
Richard A AndersonCentre for Reproductive Health, Institute of Regeneration and Repair, Edinburgh, UK.ORCID 0000-0002-7495-518X
Sean D LawleyDepartment of Mathematics, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-2208-026X

Funding

Medical Research Council MR/R003246/1Medical Research Council MR/W019140/1National Science Foundation NSF CAREER DMS-1944574National Science Foundation NSF DMS-2325258National Science Foundation NSF DMS-2325259Wellcome TrustWellcome Trust 215625/Z/19/Z
6 · The paper itself

Abstract

backgroundWomen are increasingly choosing to delay childbirth, and those with low ovarian reserves indicative of primary ovarian insufficiency are at risk for sub- and infertility and also the early onset of menopause. Experimental strategies that promise to extend the duration of ovarian function in women are currently being developed. One strategy is to slow the rate of loss of existing primordial follicles (PFs), and a second is to increase, or 'boost', the number of autologous PFs in the human ovary. In both cases, the duration of ovarian function would be expected to be lengthened, and menopause would be delayed. This might be accompanied by an extended production of mature oocytes of sufficient quality to extend the fertile lifespan. OBJECTIVE AND RATIONALE: In this work, we consider how slowing physiological ovarian aging might improve the health and well-being of patients, and summarize the current state-of-the-art of approaches being developed. We then use mathematical modeling to determine how interventions are likely to influence the duration of ovarian function quantitatively. Finally, we consider efficacy benchmarks that should be achieved so that individuals will benefit, and propose criteria that could be used to monitor ongoing efficacy in different patients as these strategies are being validated. SEARCH

methodsCurrent methods to estimate the size of the ovarian reserve and its relationship to the timing of the menopausal transition and menopause were compiled, and publications establishing methods designed to slow loss of the ovarian reserve or to deliver additional ovarian PFs to patients were identified. OUTCOMES: We review our current understanding of the consequences of reproductive aging in women, and compare different approaches that may extend ovarian function in women at risk for POI. We also provide modeling of primordial reserve decay in the presence of therapies that slow PF loss or boost PF numbers. An interactive online tool is provided that estimates how different interventions would impact the duration of ovarian function across the natural population. Modeling output shows that treatments that slow PF loss would need to be applied as early as possible and for many years to achieve significant delay of menopause. In contrast, treatments that add additional PFs should occur as late as possible relative to the onset of menopause. Combined approaches slowing ovarian reserve loss while also boosting numbers of (new) PFs would likely offer some additional benefits in delaying menopause. WIDER IMPLICATIONS: Extending ovarian function, and perhaps the fertile lifespan, is on the horizon for at least some patients. Modeling ovarian aging with and without such interventions complements and helps guide the clinical approaches that will achieve this goal. REGISTRATION NUMBER: Not applicable.

Indexed as

Models, BiologicalOvarian FollicleOvarian ReserveOvaryPrimary Ovarian InsufficiencyFemaleHumansMenopauseagingfollicle reservemenopauseoocyteovaryprimordial follicles

Identifiers

PMID40324778
PMCPMC12405616

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.